AI in Healthcare

The pharmaceutical industry is experiencing a profound shift thanks to generative AI. New research from IBM Research, published today, highlights that these advanced AI models are reducing preclinical drug development timelines by an average of 30%. This acceleration is not merely an incremental improvement; it's a fundamental change in how we discover and develop life-saving medications. What are the ethical considerations and regulatory challenges we need to address to fully harness this potential responsibly? I believe interdisciplinary collaboration is key to navigating this rapidly evolving landscape. Source: "Accelerating Drug Discovery: The Role of Generative AI in 2026" from IBM Research, published July 16, 2026. Find the full report here: https://research.ibm.com/blog/2026/ai-drug-discovery.html View and join any or all of our communities โ€” AI, quantum, and real estate: https://alex-companies.com/linkedin/groups If there's an AI, quantum, or real estate community you'd like to see us convene, tell us โ€” this portfolio grows by request. MIT & Google-Trained Cross-Domain AI Expert. Quantum - AI Advocate. Democratized Blue Ocean Strategist & Operator. Real Estate Strategy & Intelligence Leader. George Arnold Alexander, III Associate Broker, ALEX.RealEstate Intelligence Officer, ALEX Intelligence +1 713.918.9951 ยท [email protected]
Licensed by the Texas Real Estate Commission. Broker: Alexander Tiffany Southwest, LLC · License #565194-BB.
Diane Hart Alexander, Chair & CEO, ALEX Companies · Designated Broker · #574877-B  ·  George Arnold Alexander III, Partner, ALEX Companies · Associate Broker · #574878-B
Texas Real Estate Commission Information About Brokerage Services · TREC Consumer Protection Notice · trec.texas.gov